AMENDMENTS TO THE CLAIMS:

Please replace the claims with the claims provided in the listing below wherein status, amendments, additions and cancellations are indicated.

1. (Original) A hyperthermia agent for malignant tumor which comprises cytokine and magnetic fine particles.

2. (Original) A hyperthermia agent for malignant tumor which comprises a vector into which a cytokine gene is integrated so that cytokine can be expressed in a malignant tumor cell and magnetic fine particles.

3. (Original) The hyperthermia agent according to Claim 1 or 2, wherein the magnetic fine particles are magnetic fine particles on the surface of which is bound to an antibody which selectively binds to malignant tumor cells.

4. (Original) The hyperthermia agent according to Claim 1 or 2, wherein the magnetic fine particles are magnetite.

5. (Original) The hyperthermia agent according to Claim 4, wherein the magnetite is a magnetite covered by cationic liposome.

6. (Currently amended) The hyperthermia agent according to ~~any one of Claims~~ Claim 1[[,]] or 2 ~~and 5~~, wherein the cytokine is at least one cytokine selected from the group consisting of interleukin-2, granulocyte macrophage colony stimulating factor, interleukin-4, interleukin-12, interferon-ß, interferon-γ, and tumor necrosis factor-α.

7. (Original) The hyperthermia agent according to Claim 3, wherein the cytokine is at least one cytokine selected from the group consisting of interleukin-2, granulocyte macrophage colony stimulating factor, interleukin-4, interleukin-12, interferon-β, interferon-γ, and tumor necrosis factor-α.

8. (Original) The hyperthermia agent according to Claim 4, wherein the cytokine is at least one cytokine selected from the group consisting of interleukin-2, granulocyte macrophage colony stimulating factor, interleukin-4, interleukin-12, interferon-β, interferon-γ, and tumor necrosis factor-α.

9. (Original) The hyperthermia agent according to Claim 6, wherein the cytokine is interleukin-2.

10. (Original) The hyperthermia agent according to Claim 7, wherein the cytokine is interleukin-2.

11. (Original) The hyperthermia agent according to Claim 8, wherein the cytokine is interleukin-2.

12. (Original) The hyperthermia agent according to Claim 6, wherein the cytokine is a granulocyte macrophage colony stimulating factor.

13. (Original) The hyperthermia agent according to Claim 7, wherein the cytokine is a granulocyte macrophage colony stimulating factor.

14. (Original) The hyperthermia agent according to Claim 8, wherein the cytokine is a granulocyte macrophage colony stimulating factor.

15. (Currently amended) The hyperthermia agent according to ~~any one of Claims 1, 2, 5 and 7 to 14~~ Claim 1 or 2, wherein the agent contains cytokine or a vector in which a cytokine gene is integrated so that cytokine can express in malignant tumor cells, and magnetic fine particles in combination or separately.

16. (Original) The hyperthermia agent according to Claim 3, wherein the agent contains cytokine or a vector in which a cytokine gene is integrated so that cytokine can express in malignant tumor cells, and magnetic fine particles in combination or separately.

17. (Original) The hyperthermia agent according to Claim 4, wherein the agent contains cytokine or a vector in which a cytokine gene is integrated so that cytokine can express in malignant tumor cells, and magnetic fine particles in combination or separately.

18. (Original) The hyperthermia agent according to Claim 6, wherein the agent contains cytokine or a vector in which a cytokine gene is integrated so that cytokine can express in malignant tumor cells, and magnetic fine particles in combination or separately.

19. (Original) A method of using cytokine for hyperthermia of malignant tumor.

20. (Original) A hyperthermia method of malignant tumor which comprises administering cytokine to malignant tumor, then the malignant tumor is subjected to hyperthermia.

21. (Original) A method of using a cytokine gene in hyperthermia of malignant tumor.

22. (Original) A hyperthermia method of malignant tumor which comprises introducing a vector into which a cytokine gene is integrated, so that it can express the cytokine in malignant tumor cells, into malignant tumor whereby expressing the cytokine in the malignant tumor cells, then subjecting the malignant tumor tissue to hyperthermia.

23. (New) The hypothermia agent according to claim 5, wherein the cytokine is at least one cytokine selected from the group consisting of interleukin-2, granulocyte macrophage colony stimulating factor, interleukin-4, interleukin-12, interferon-ß, interferon-γ, and tumor necrosis factor-α.

24. (New) The hypothermia agent according to claim 5, wherein the agent contains cytokine or a vector in which a cytokine gene is integrated so that

cytokine can express in malignant tumor cells, and magnetic fine particles in combination or separately.

25. (New) The hypothermia agent according to claim 7, wherein the agent contains cytokine or a vector in which a cytokine gene is integrated so that cytokine can express in malignant tumor cells, and magnetic fine particles in combination or separately.

26. (New) The hypothermia agent according to claim 8, wherein the agent contains cytokine or a vector in which a cytokine gene is integrated so that cytokine can express in malignant tumor cells, and magnetic fine particles in combination or separately.

27. (New) The hypothermia agent according to claim 9, wherein the agent contains cytokine or a vector in which a cytokine gene is integrated so that cytokine can express in malignant tumor cells, and magnetic fine particles in combination or separately.

28. (New) The hypothermia agent according to claim 10, wherein the agent contains cytokine or a vector in which a cytokine gene is integrated so that

cytokine can express in malignant tumor cells, and magnetic fine particles in combination or separately.

29. (New) The hypothermia agent according to claim 11, wherein the agent contains cytokine or a vector in which a cytokine gene is integrated so that cytokine can express in malignant tumor cells, and magnetic fine particles in combination or separately.

30. (New) The hypothermia agent according to claim 12, wherein the agent contains cytokine or a vector in which a cytokine gene is integrated so that cytokine can express in malignant tumor cells, and magnetic fine particles in combination or separately.

31. (New) The hypothermia agent according to claim 13, wherein the agent contains cytokine or a vector in which a cytokine gene is integrated so that cytokine can express in malignant tumor cells, and magnetic fine particles in combination or separately.

32. (New) The hypothermia agent according to claim 14, wherein the agent contains cytokine or a vector in which a cytokine gene is integrated so that

cytokine can express in malignant tumor cells, and magnetic fine particles in combination or separately.